Nasally administered Lactobacillus rhamnosus accelerate the recovery of humoral immunity in B lymphocyte-deficient malnourished mice.
- 2013-02
- The Journal of Nutrition 143(2)
- N. Barbieri
- J. Villena
- M. Herrera
- S. Salva
- S. Alvarez
- PubMed: 23269656
- DOI: 10.3945/jn.112.165811
Abstract
The ability of nasally administered Lactobacillus rhamnosus CRL1505 to accelerate the recovery of respiratory B cell-mediated immunity against pneumococcal infection in replete malnourished mice was evaluated. Weaned mice were malnourished after consumption of a protein-free diet for 21 d. Malnourished mice were fed a balanced conventional diet (BCD) for 7 d (BCD group) or a BCD for 7 d with supplemental L. rhamnosus CRL1505 by the nasal route during the last 2 d (BCD+Lr group). Nonreplete malnourished and normal mice were used as the malnourished (MNC) and the well-nourished (WNC) control groups, respectively. Mice were challenged with Streptococcus pneumoniae at the end of each dietary treatment. The immune response was studied before the challenge and at different times postinfection. The MNC mice had less resistance to pneumococcal infection, fewer mature and immature B cells in lung and spleen, and a reduced production of specific antibodies compared with WNC mice. The BCD treatment did not induce a complete normalization of the number B cell populations and antibody amounts. However, the BCD+Lr group had normal numbers of spleen and lung B cells. Moreover, the BCD+Lr mice had a significantly lower susceptibility to S. pneumoniae infection and higher amounts of anti-pneumococcal antibodies. Although further studies are necessary to clarify the effect of malnutrition and nasally administered lactobacilli in other immune cell populations involved in the protection against respiratory pathogens, this work gives evidence of the importance of using nasal priming with probiotics to accelerate the recovery of respiratory immunity in immunocompromised malnourished hosts.
Research Insights
Supplement | Health Outcome | Effect Type | Effect Size |
---|---|---|---|
Lactobacillus rhamnosus CLR1505 | Enhanced Antibody Production | Beneficial | Large |
Lactobacillus rhamnosus CLR1505 | Enhanced Resistance to Streptococcus Pneumoniae Infection | Beneficial | Large |
Lactobacillus rhamnosus CLR1505 | Improved Humoral Immunity | Beneficial | Large |
Lactobacillus rhamnosus CLR1505 | Increased B Cell Populations | Beneficial | Large |
Lactobacillus rhamnosus CRL 1505 | Enhanced Antibody Production | Beneficial | Large |
Lactobacillus rhamnosus CRL 1505 | Improved Humoral Immunity | Beneficial | Large |
Lactobacillus rhamnosus CRL 1505 | Increased B Cell Populations | Beneficial | Large |
Lactobacillus rhamnosus CRL 1505 | Reduced Susceptibility to Infection | Beneficial | Large |
Lactobacillus rhamnosus LR04 | Accelerated Recovery of B Cell-Mediated Respiratory Immunity | Beneficial | Large |
Lactobacillus rhamnosus LR04 | Increased Anti-Pneumococcal Antibody Levels | Beneficial | Large |
Lactobacillus rhamnosus LR04 | Reduced Susceptibility to Pneumococcal Infection | Beneficial | Moderate |
Lactobacillus rhamnosus LR05 | Improved Immunity | Beneficial | Large |
Lactobacillus rhamnosus LR06 | Improved Immunity | Beneficial | Large |
Lactobacillus rhamnosus LR06 | Increased B Cell Count | Beneficial | Large |
Lactobacillus rhamnosus LR06 | Increased Resistance to Pneumococcal Infections | Beneficial | Large |
Lactobacillus rhamnosus LR06 | Increased Specific Antibody Production | Beneficial | Large |
Lactobacillus rhamnosus LRa05 | Improved Humoral Immunity | Beneficial | Large |
Lactobacillus rhamnosus LRa05 | Increased B Cell Populations | Beneficial | Large |
Lactobacillus rhamnosus LRa05 | Increased Specific Antibody Production | Beneficial | Large |
Lactobacillus rhamnosus LRa05 | Reduced Susceptibility to Pneumococcal Infection | Beneficial | Moderate |